Antibody-Based Therapeutics for Cancer
Organizer(s): Louis M. Weiner and Paul CarterDate: February 17 - 22, 2005
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, NM, USA
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected un-conjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphoma. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new functional targets for antibody perturbation.
Discounted Abstract Deadline: October 18 2004
Discounted Registration Deadline: December 17 2004
We gratefully acknowledge additional support for this conference from:
Bayer USA Foundation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Seattle Genetics, Inc.